Thomas Erker

3.3k total citations
133 papers, 2.6k citations indexed

About

Thomas Erker is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Thomas Erker has authored 133 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Organic Chemistry, 59 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Thomas Erker's work include Phenothiazines and Benzothiazines Synthesis and Activities (26 papers), Synthesis and biological activity (23 papers) and Synthesis and Reactivity of Sulfur-Containing Compounds (21 papers). Thomas Erker is often cited by papers focused on Phenothiazines and Benzothiazines Synthesis and Activities (26 papers), Synthesis and biological activity (23 papers) and Synthesis and Reactivity of Sulfur-Containing Compounds (21 papers). Thomas Erker collaborates with scholars based in Austria, Germany and Poland. Thomas Erker's co-authors include Norbert Handler, Thomas Szekeres, Marek Murias, Herbert Bartsch, Walter Jäger, Philipp Saiko, Wolfgang Löscher, Gerhard F. Ecker, Zsuzsanna Bagó-Horváth and Oliver Langer and has published in prestigious journals such as PLoS ONE, NeuroImage and Stroke.

In The Last Decade

Thomas Erker

126 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Erker Austria 31 1.0k 652 551 508 326 133 2.6k
Ángel Ortega Spain 31 2.2k 2.2× 282 0.4× 408 0.7× 585 1.2× 121 0.4× 44 4.5k
Sandhya Mandlekar United States 28 2.1k 2.1× 445 0.7× 846 1.5× 92 0.2× 104 0.3× 70 3.6k
Emidio Camaioni Italy 31 1.6k 1.6× 568 0.9× 1.2k 2.1× 62 0.1× 284 0.9× 113 3.8k
John E. Oatis United States 18 1.1k 1.1× 147 0.2× 248 0.5× 925 1.8× 231 0.7× 40 2.5k
Wanda Baer‐Dubowska Poland 35 2.0k 1.9× 335 0.5× 279 0.5× 409 0.8× 63 0.2× 136 3.5k
Sawsan A. Zaitone Egypt 30 782 0.8× 223 0.3× 203 0.4× 71 0.1× 200 0.6× 119 2.4k
Valeria Pittalà Italy 35 1.9k 1.8× 552 0.8× 168 0.3× 40 0.1× 266 0.8× 132 3.2k
Amal Kaddoumi United States 40 1.2k 1.2× 519 0.8× 858 1.6× 26 0.1× 224 0.7× 110 4.1k
Ka‐Yun Ng United States 26 723 0.7× 79 0.1× 377 0.7× 194 0.4× 69 0.2× 53 2.1k
Betty Yuen Kwan Law Macao 38 2.3k 2.3× 201 0.3× 358 0.6× 134 0.3× 168 0.5× 130 4.2k

Countries citing papers authored by Thomas Erker

Since Specialization
Citations

This map shows the geographic impact of Thomas Erker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Erker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Erker more than expected).

Fields of papers citing papers by Thomas Erker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Erker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Erker. The network helps show where Thomas Erker may publish in the future.

Co-authorship network of co-authors of Thomas Erker

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Erker. A scholar is included among the top collaborators of Thomas Erker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Erker. Thomas Erker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Erker, Thomas, et al.. (2019). Functional characterization of novel bumetanide derivatives for epilepsy treatment. Neuropharmacology. 162. 107754–107754. 18 indexed citations
2.
Huang, Huachen, Mohammad Iqbal H. Bhuiyan, Tong Jiang, et al.. (2019). A Novel Na + -K + -Cl − Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke. Stroke. 50(4). 1021–1025. 36 indexed citations
3.
Kucińska, Małgorzata, et al.. (2018). The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines. Investigational New Drugs. 37(5). 849–864. 5 indexed citations
4.
Römermann, Kerstin, Maren Fedrowitz, Kathrin Töllner, et al.. (2017). Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain. Neuropharmacology. 117. 182–194. 58 indexed citations
5.
Kucińska, Małgorzata, Hanna Piotrowska‐Kempisty, Natalia Lisiak, et al.. (2016). Selective anticancer activity of the novel thiobenzanilide 63T against human lung adenocarcinoma cells. Toxicology in Vitro. 37. 148–161. 4 indexed citations
6.
Khom, Sophia, Igor Baburin, Thomas Erker, et al.. (2013). GABAA receptor modulation by piperine and a non-TRPV1 activating derivative. Biochemical Pharmacology. 85(12). 1827–1836. 45 indexed citations
7.
Fallarero, Adyary, Gerda Brunhofer, Przemysław Guzik, et al.. (2011). Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation. European Journal of Pharmaceutical Sciences. 45(1-2). 169–183. 26 indexed citations
8.
Shabbir, Waheed, Eugen Timin, Thomas Erker, et al.. (2011). Interaction of Diltiazem with an Intracellularly Accessible Binding Site on CaV1.2. Biophysical Journal. 100(3). 568a–568a. 5 indexed citations
9.
Nemeth, Johannes, Aiman Abrahim, Peter Matzneller, et al.. (2011). The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. Journal of Antimicrobial Chemotherapy. 66(4). 834–839. 48 indexed citations
10.
11.
Shabbir, Waheed, et al.. (2010). Interaction of diltiazem with an intracellularly accessible binding site on CaV1.2. British Journal of Pharmacology. 162(5). 1074–1082. 11 indexed citations
12.
Brunhofer, Gerda, Christian Studenik, Gerhard F. Ecker, & Thomas Erker. (2010). Synthesis, spasmolytic activity and structure–activity relationship study of a series of polypharmacological thiobenzanilides. European Journal of Pharmaceutical Sciences. 42(1-2). 37–44. 13 indexed citations
13.
Bernhaus, Astrid, Mária Ozsvár-Kozma, Philipp Saiko, et al.. (2008). Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Investigational New Drugs. 27(5). 393–401. 23 indexed citations
14.
Brunhofer, Gerda, et al.. (2008). Benzanilides with spasmolytic activity: Chemistry, pharmacology, and SAR. Bioorganic & Medicinal Chemistry. 16(11). 5974–5981. 11 indexed citations
15.
16.
Murias, Marek, Walter Jäger, Norbert Handler, et al.. (2005). Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship. Biochemical Pharmacology. 69(6). 903–912. 270 indexed citations
17.
Erker, Thomas, et al.. (2005). Synthesis and pharmacological profile of non-peptide vasopressin antagonists. European Journal of Pharmaceutical Sciences. 24(5). 421–431. 5 indexed citations
18.
Murias, Marek, Norbert Handler, Thomas Erker, et al.. (2004). Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure–activity relationship. Bioorganic & Medicinal Chemistry. 12(21). 5571–5578. 247 indexed citations
19.
Erker, Thomas, et al.. (2003). Atypisches Verhalten von Thiophenderivaten gegeniiber Reduktions- bzw. Thionierungs-Versuchen. Scientia Pharmaceutica. 71(2). 51–56. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ángel Ortega Breakdown of academic impact, for papers by Sandhya Mandlekar Breakdown of academic impact, for papers by Emidio Camaioni Breakdown of academic impact, for papers by John E. Oatis Breakdown of academic impact, for papers by Wanda Baer‐Dubowska Breakdown of academic impact, for papers by Sawsan A. Zaitone Breakdown of academic impact, for papers by Valeria Pittalà Breakdown of academic impact, for papers by Amal Kaddoumi Breakdown of academic impact, for papers by Ka‐Yun Ng Breakdown of academic impact, for papers by Betty Yuen Kwan Law
Rankless by CCL
2026